Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

141.47 +1.92 (+1.38%)

Streaming Delayed Price Updated: 11:12 AM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

70 71 Next >

Gilead Sciences to Present at Upcoming Investor Conference

December 22, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes ↗

December 22, 2025

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Via Benzinga

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 22, 2025

From Gilead Sciences, Inc.

Via Business Wire

Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal ↗

December 20, 2025

Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.

Via Benzinga

Topics Government

Why Gilead Sciences (GILD) Stock Is Up Today

December 19, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive...

Via StockStory

Topics Earnings

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗

December 19, 2025

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Via Investor's Business Daily

Topics Government Stocks

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

December 19, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Inc. (NASDAQ:GILD): A High-Quality Dividend Stock for Reliable Income ↗

December 19, 2025

Gilead Sciences (GILD) offers a reliable 2.56% dividend yield, backed by strong profitability, a debt-free balance sheet, and a decade of consistent payouts.

Via Chartmill

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Via Stocktwits

Topics Economy Government

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

December 18, 2025

From Gilead Sciences, Inc.

Via Business Wire

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

December 17, 2025

Via Benzinga

Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal ↗

December 15, 2025

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Via Benzinga

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains ↗

December 15, 2025

Via MarketBeat

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

December 15, 2025

From Gilead Sciences, Inc.

Via Business Wire

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗

December 12, 2025

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead-partnered cancer regimen failed.

Via Investor's Business Daily

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

December 12, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗

December 12, 2025

Gilead Sciences (GILD) presents a strong value investing case, trading at a discount to its industry with high profitability, no debt, and improving earnings growth forecasts.

Via Chartmill

3 Profitable Stocks We Keep Off Our Radar

December 10, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

December 09, 2025

From Gilead Sciences, Inc.

Via Business Wire

What Does the Market Think About Gilead Sciences Inc? ↗

December 08, 2025

Via Benzinga

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

December 07, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

3 Unpopular Stocks We Think Twice About

December 03, 2025

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗

December 01, 2025

Via MarketBeat

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

November 28, 2025

Via Benzinga

Top S&P500 movers in Friday's session ↗

November 28, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.